GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Operating Margin %

Genvec (Genvec) Operating Margin % : -2,900.88% (As of Mar. 2017)


View and export this data going back to 2000. Start your Free Trial

What is Genvec Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Genvec's Operating Income for the three months ended in Mar. 2017 was $-3.31 Mil. Genvec's Revenue for the three months ended in Mar. 2017 was $0.11 Mil. Therefore, Genvec's Operating Margin % for the quarter that ended in Mar. 2017 was -2,900.88%.

The historical rank and industry rank for Genvec's Operating Margin % or its related term are showing as below:


GNVC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -171.86
* Ranked among companies with meaningful Operating Margin % only.

Genvec's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Genvec's Operating Income for the three months ended in Mar. 2017 was $-3.31 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2017 was $-8.66 Mil.


Genvec Operating Margin % Historical Data

The historical data trend for Genvec's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Operating Margin % Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -150.72 -279.58 -42.00 -742.03 -1,411.94

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -641.03 -6,592.31 -884.39 -9,600.00 -2,900.88

Competitive Comparison of Genvec's Operating Margin %

For the Biotechnology subindustry, Genvec's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genvec's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genvec's Operating Margin % falls into.



Genvec Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genvec's Operating Margin % for the fiscal year that ended in Dec. 2016 is calculated as

Operating Margin %=Operating Income (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=-7.215 / 0.511
=-1,411.94 %

Genvec's Operating Margin % for the quarter that ended in Mar. 2017 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2017 ) / Revenue (Q: Mar. 2017 )
=-3.307 / 0.114
=-2,900.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genvec  (NAS:GNVC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genvec Operating Margin % Related Terms

Thank you for viewing the detailed overview of Genvec's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011